TY - JOUR
T1 - Use of Statins in Patients with Chronic Liver Disease and Cirrhosis
T2 - Current Views and Prospects
AU - Vargas, Jose Ignacio
AU - Arrese, Marco
AU - Shah, Vijay H.
AU - Arab, Juan Pablo
N1 - Funding Information:
This work was supported by grant(s) NIH DK59615 and AA021171 (VHS), the Clinical Core of the Mayo Clinic Center for Cell Signaling in Gastroenterology (P30DK084567). Arab JP was founded by an award from AASLD Foundation (AASLD/LIFER Clinical and Translational Research Fellowship in Liver Diseases 2016). Support from the government of Chile through the Fondo Nacional de Desarrollo Cientıfico y Tecnologico (FONDECYT 1150327 to M.A.) and the Comision Nacional de Investigacion Cientıfica y Tecnologica (grant CONICYTPIA/Basal PFB12, Basal Centre for Excellence in Science and Technology to M.A.) is also acknowledged.
Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Purpose of review: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. Recent findings: Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. Summary: In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.
AB - Purpose of review: The purpose of this study is to analyze the current evidence regarding the use of statins in patients with chronic liver disease and cirrhosis. Recent findings: Chronic liver disease (CLD), cirrhosis, and its complications, including hepatocellular carcinoma (HCC), are significant public health problems. The use of statins in patients with CLD has been a matter of concern, and physicians are often reluctant to its prescription in these patients. This mainly relates to the potential occurrence of drug-induced liver injury. However, newer evidence from pre-clinical and clinical research has shown that statins are drugs with a potentially beneficial impact on the natural history of cirrhosis, on portal hypertension, and in HCC prevention. Summary: In this review, we summarize current evidence regarding the influence of statins in endothelial dysfunction in CLD, their ability to modulate hepatic fibrogenesis, and their vasoprotective effects in portal hypertension; we also focus on existing data about the impact of statins in cirrhosis development, progression, and complications and critically assess the current concerns about its use in patients with CLD.
KW - Chronic liver diseases
KW - Cirrhosis
KW - Drug-induced liver injury
KW - HMG-CoA reductase inhibitors
KW - Hepatocellular carcinoma
KW - Portal hypertension
KW - Statins
KW - Variceal bleeding
UR - http://www.scopus.com/inward/record.url?scp=85026643973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026643973&partnerID=8YFLogxK
U2 - 10.1007/s11894-017-0584-7
DO - 10.1007/s11894-017-0584-7
M3 - Review article
C2 - 28752475
AN - SCOPUS:85026643973
VL - 19
JO - Current Gastroenterology Reports
JF - Current Gastroenterology Reports
SN - 1522-8037
IS - 9
M1 - 43
ER -